...
首页> 外文期刊>Antibiotics >Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery
【24h】

Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery

机译:生物合成叶酸途径在抗菌药物发现中的目标实用程序。

获取原文

摘要

The need for new antimicrobials is great in face of a growing pool of resistant pathogenic organisms. This review will address the potential for antimicrobial therapy based on polypharmacological activities within the currently utilized bacterial biosynthetic folate pathway. The folate metabolic pathway leads to synthesis of required precursors for cellular function and contains a critical node, dihydrofolate reductase (DHFR), which is shared between prokaryotes and eukaryotes. The DHFR enzyme is currently targeted by methotrexate in anti-cancer therapies, by trimethoprim for antibacterial uses, and by pyrimethamine for anti-protozoal applications. An additional anti-folate target is dihyropteroate synthase (DHPS), which is unique to prokaryotes as they cannot acquire folate through dietary means. It has been demonstrated as a primary target for the longest standing antibiotic class, the sulfonamides, which act synergistically with DHFR inhibitors. Investigations have revealed most DHPS enzymes possess the ability to utilize sulfa drugs metabolically, producing alternate products that presumably inhibit downstream enzymes requiring the produced dihydropteroate. Recent work has established an off-target effect of sulfonamide antibiotics on a eukaryotic enzyme, sepiapterin reductase, causing alterations in neurotransmitter synthesis. Given that inhibitors of both DHFR and DHPS are designed to mimic their cognate substrate, which contain shared substructures, it is reasonable to expect such “off-target” effects. These inhibitors are also likely to interact with the enzymatic neighbors in the folate pathway that bind products of the DHFR or DHPS enzymes and/or substrates of similar substructure. Computational studies designed to assess polypharmacology reiterate these conclusions. This leads to hypotheses exploring the vast utility of multiple members of the folate pathway for modulating cellular metabolism, and includes an appealing capacity for prokaryotic-specific polypharmacology for antimicrobial applications.
机译:面对越来越多的耐药病原微生物,对新的抗菌药物的需求很大。这篇综述将探讨基于目前利用的细菌生物合成叶酸途径中的多种药理活性的抗微生物治疗的潜力。叶酸代谢途径导致细胞功能所需前体的合成,并包含一个关键节点,二氢叶酸还原酶(DHFR),在原核生物和真核生物之间共享。 DHFR酶目前在抗癌疗法中被甲氨蝶呤靶向,在抗菌用途中被甲氧苄啶靶向,在抗原生动物应用中被乙胺嘧啶靶向。另一种抗叶酸靶标是二氢蝶呤合酶(DHPS),原核生物无法通过饮食获取叶酸,因此该酶是唯一的。它已被证明是存在时间最长的抗生素类别的主要目标,磺胺类药物可与DHFR抑制剂协同作用。研究表明,大多数DHPS酶具有代谢利用磺胺类药物的能力,产生了可能抑制需要产生二氢蝶呤的下游酶的替代产品。最近的工作已经建立了磺酰胺类抗生素对真核酶Sepaapterin还原酶的脱靶作用,引起神经递质合成的改变。假设DHFR和DHPS的抑制剂均被设计为模仿它们的同源底物(包含共有的亚结构),则可以预期出现这种“脱靶”效应。这些抑制剂也可能与叶酸途径中的酶促邻居相互作用,后者结合DHFR或DHPS酶的产物和/或相似亚结构的底物。旨在评估多元药理学的计算研究重申了这些结论。这导致假说探索了叶酸途径的多个成员在调节细胞代谢中的广泛应用,并且包括针对抗菌应用的原核特异性多药理学的吸引力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号